In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Authors:	Geoffrey H Trew Adam P Brown Samantha Gillard Stuart Blackmore Christine Clewlow Paul O'Donohoe Radoslaw Wasiak

Institution:	1.Consultant in Reproductive Medicine and Surgery,Hammersmith Hospital,London,UK;2.Abacus International,Manchester,UK;3.Abacus International,Bicester,Oxfordshire,UK;4.Formerly from Merck Serono,Feltham,Middlesex, UK;5.Merck Serono,Feltham,Middlesex,UK;6.United BioSource Corporation,London,UK

Abstract:	Background Previous studies have reported conflicting results for the comparative doses of recombinant follicle stimulating hormone (rFSH) and highly purified human menopausal gonadotrophin (hMG-HP) required per cycle of in vitro fertilisation (IVF); the aim of this study was to determine the average total usage of rFSH versus hMG-HP in a 'real-world' setting using routine clinical practice.

Keywords:
本文献已被 SpringerLink 等数据库收录！